386 related articles for article (PubMed ID: 10389946)
21. Quantitative high-performance liquid chromatographic method for pharmacokinetic studies of the potent mast cell inhibitor 4-(4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline (WHI-P131).
Chen CL; Malaviya R; Chen H; Liu XP; Uckun FM
J Chromatogr B Biomed Sci Appl; 1999 Apr; 727(1-2):205-12. PubMed ID: 10360439
[TBL] [Abstract][Full Text] [Related]
22. Genetic and biochemical evidence for a critical role of Janus kinase (JAK)-3 in mast cell-mediated type I hypersensitivity reactions.
Malaviya R; Uckun FM
Biochem Biophys Res Commun; 1999 Apr; 257(3):807-13. PubMed ID: 10208864
[TBL] [Abstract][Full Text] [Related]
23. Computational analyses of JAK1 kinase domain: subtle changes in the catalytic cleft influence inhibitor specificity.
Zhang X; Hu Y; Yuan Z
Biochem Biophys Res Commun; 2008 May; 370(1):72-6. PubMed ID: 18346458
[TBL] [Abstract][Full Text] [Related]
24. Targeting Janus kinase 3 to attenuate the severity of acute graft-versus-host disease across the major histocompatibility barrier in mice.
Cetkovic-Cvrlje M; Roers BA; Waurzyniak B; Liu XP; Uckun FM
Blood; 2001 Sep; 98(5):1607-13. PubMed ID: 11520814
[TBL] [Abstract][Full Text] [Related]
25. JAK protein kinase inhibitors.
Thompson JE
Drug News Perspect; 2005 Jun; 18(5):305-10. PubMed ID: 16193102
[TBL] [Abstract][Full Text] [Related]
26. The specificity of JAK3 kinase inhibitors.
Changelian PS; Moshinsky D; Kuhn CF; Flanagan ME; Munchhof MJ; Harris TM; Whipple DA; Doty JL; Sun J; Kent CR; Magnuson KS; Perregaux DG; Sawyer PS; Kudlacz EM
Blood; 2008 Feb; 111(4):2155-7. PubMed ID: 18094329
[TBL] [Abstract][Full Text] [Related]
27. Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.
Losdyck E; Hornakova T; Springuel L; Degryse S; Gielen O; Cools J; Constantinescu SN; Flex E; Tartaglia M; Renauld JC; Knoops L
J Biol Chem; 2015 Nov; 290(48):29022-34. PubMed ID: 26446793
[TBL] [Abstract][Full Text] [Related]
28. [Inhibition of constitutively activated Jak3 and induction of apoptosis in NALM-6 cell line].
Hu W; Zhang C; Zhang P; Wei D; Zhao Z; Cai M
Hua Xi Yi Ke Da Xue Xue Bao; 2002 Jan; 33(1):25-7. PubMed ID: 12599420
[TBL] [Abstract][Full Text] [Related]
29. 4-[3-Bromo-4-hydroxyphenyl)amino]-6,7-dimethoxyquinazolin-1-ium chloride methanol solvate and 4-[(3-hydroxyphenyl)amino]-6,7-dimethoxy-1-quinazolinium chloride.
Ghosh S; Jennissen JD; Liu XP; Uckun FM
Acta Crystallogr C; 2001 Jan; 57(Pt 1):76-8. PubMed ID: 11173405
[TBL] [Abstract][Full Text] [Related]
30. Targeting Janus tyrosine kinase 3 (JAK3) with an inhibitor induces secretion of TGF-β by CD4+ T cells.
Cetkovic-Cvrlje M; Olson M; Ghate K
Cell Mol Immunol; 2012 Jul; 9(4):350-60. PubMed ID: 22728763
[TBL] [Abstract][Full Text] [Related]
31. 4-(3'-Bromo-4'hydroxylphenyl)-amino-6,7-dimethoxyquinazoline: a novel quinazoline derivative with potent cytotoxic activity against human glioblastoma cells.
Narla RK; Liu XP; Myers DE; Uckun FM
Clin Cancer Res; 1998 Jun; 4(6):1405-14. PubMed ID: 9626456
[TBL] [Abstract][Full Text] [Related]
32. Role of a JAK3-dependent biochemical signaling pathway in platelet activation and aggregation.
Tibbles HE; Vassilev A; Wendorf H; Schonhoff D; Zhu D; Lorenz D; Waurzyniak B; Liu XP; Uckun FM
J Biol Chem; 2001 May; 276(21):17815-22. PubMed ID: 11278899
[TBL] [Abstract][Full Text] [Related]
33. Inhibitors of JAK2 and JAK3: an update on the patent literature 2010 - 2012.
Dymock BW; See CS
Expert Opin Ther Pat; 2013 Apr; 23(4):449-501. PubMed ID: 23367873
[TBL] [Abstract][Full Text] [Related]
34. Prevention of DMBA-induced mammary gland tumors in mice by a dual-function inhibitor of JAK3 and EGF receptor tyrosine kinases.
Sahin K; Yabas M; Orhan C; Tuzcu M; Sahin TK; Ozercan IH; Qazi S; Uckun FM
Expert Opin Ther Targets; 2020 Apr; 24(4):379-387. PubMed ID: 32106727
[No Abstract] [Full Text] [Related]
35. [Specific function of STAT5 in regulation of proliferation of chronic leukemia K562 cells: inhibitory effect of WHI-P131].
Mitiushova EV; Aksenov ND; Marakhova II
Tsitologiia; 2010; 52(2):184-90. PubMed ID: 20352702
[TBL] [Abstract][Full Text] [Related]
36. Effect of Janus kinase 3 on the peptide transporters PEPT1 and PEPT2.
Warsi J; Hosseinzadeh Z; Dong L; Pakladok T; Umbach AT; Bhavsar SK; Shumilina E; Lang F
J Membr Biol; 2013 Dec; 246(12):885-92. PubMed ID: 23934551
[TBL] [Abstract][Full Text] [Related]
37. A novel indole-3-propanamide exerts its immunosuppressive activity by inhibiting JAK3 in T cells.
Carbonnelle D; Duflos M; Marchand P; Chauvet C; Petit JY; Lang F
J Pharmacol Exp Ther; 2009 Nov; 331(2):710-6. PubMed ID: 19710367
[TBL] [Abstract][Full Text] [Related]
38. The Role of Janus Kinase 3 in the Regulation of Na⁺/K⁺ ATPase under Energy Depletion.
Hosseinzadeh Z; Honisch S; Schmid E; Jilani K; Szteyn K; Bhavsar S; Singh Y; Palmada M; Umbach AT; Shumilina E; Lang F
Cell Physiol Biochem; 2015; 36(2):727-40. PubMed ID: 26021261
[TBL] [Abstract][Full Text] [Related]
39. Prevention of UVB-induced skin inflammation, genotoxicity, and photocarcinogenesis in mice by WHI-P131, a dual-function inhibitor of Janus kinase 3 and EGF receptor kinase.
Uckun FM; Dibirdik I; Qazi S
Arzneimittelforschung; 2010; 60(4):218-25. PubMed ID: 20486473
[TBL] [Abstract][Full Text] [Related]
40. Differential substrate recognition capabilities of Janus family protein tyrosine kinases within the interleukin 2 receptor (IL2R) system: Jak3 as a potential molecular target for treatment of leukemias with a hyperactive Jak-Stat signaling machinery.
Witthuhn BA; Williams MD; Kerawalla H; Uckun FM
Leuk Lymphoma; 1999 Jan; 32(3-4):289-97. PubMed ID: 10037026
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
